Xiangxue Pharmaceutical released its 2026 interim report. As of June 30, total operating revenue was 703 million yuan, down 14.09 percent year on year. Net loss attributable to the parent company was 269 million yuan, an increase of 34.95 million yuan compared with the same period last year, widening the loss. Net cash flow from operating activities was negative 90.43 million yuan. The asset-liability ratio rose to 103.57 percent. Gross margin was 32.38 percent, and diluted earnings per share was negative 0.41 yuan. The company had 25,400 shareholders, and the top ten shareholders held 31.83 percent of total share capital.
Xiangxue PharmaceuticalNet loss widened to 269 million yuan, revenue fell 14.09%, and asset-liability ratio rose to 103.57%.
